Alimera Sciences Prices Initial Public Offering
Shares Now Trading on NASDAQ Global Market Under Symbol “ALIM”
ATLANTA, Apr 23, 2010 — Alimera Sciences, Inc. (Nasdaq:ALIM), (“Alimera”) today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.
In addition, Alimera has granted the underwriters a 30-day option to purchase up to an additional 982,500 shares to cover over-allotments, if any. The gross proceeds of the offering, before expenses, from the sale of shares, are expected to be $72.05 million, assuming the 30-day over-allotment option is not exercised. The closing of the offering is expected to take place on April 27, 2010.
Credit Suisse Securities (USA) LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering.
Shares of Alimera common stock began trading on the NASDAQ Global Market under the symbol “ALIM” on Thursday, April 22, 2010.
This registration statement relating to the initial public offering of shares of common stock of Alimera has been declared effective by the U.S. Securities and Exchange Commission.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The offering of common stock may be made only by means of a prospectus and prospectus supplement. Copies of the prospectus and prospectus supplement may be obtained upon request to Credit Suisse Securities (USA) LLC, One Madison Avenue, New York, New York 10010, Attention: Prospectus Department, or via telephone at 1-800-221-1037; or to Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, Attention: Prospectus Department, or by calling toll-free at 1-877-858-5407.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, statements relating to expectations, projections, estimates, goals, plans, objectives and future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements. Factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in greater detail under the heading “Risk Factors” contained in our preliminary prospectus supplement filed with the Securities and Exchange Commission on April 6, 2010. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. You should keep in mind that any forward-looking statement made by Alimera herein, or elsewhere, speaks only as of the date on which made. New risks and uncertainties arise from time to time, and it is impossible for Alimera to predict these events, or how they may affect it. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.